Back to mobile site

Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale

August 28, 2026 6:17 AM EDT Send to a Friend
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has placed a stalking horse bid to acquire certain assets from BioXcel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login